Entering text into the input field will update the search result below

Intrexon to acquire GenVec in all-stock deal

Jan. 24, 2017 9:17 AM ETPrecigen, Inc. (PGEN) StockBy: Douglas W. House, SA News Editor7 Comments
  • Intrexon (XON) has agreed to acquire GenVec (GNVC) in an all-stock transaction that values GenVec at $7/share, a 54% premium to yesterday's close of $4.54. GenVec shareholders will receive 0.297 of a share of XON for each GNVC common share owned. GNVC shareholders will also be eligible to receive contingent consideration equal to 50% of any milestone or royalty payments received within 36 months of the close of the deal under GenVec's agreement with Novartis (NVS). The transaction should close next quarter.
  • Intrexon intends to integrate and expand upon GenVec's expertise in adenoviral vectors and cGMP drug product manufacturing with the aim of enhancing its gene transfer capabilities that encompass multiple viral and non-viral platforms.

Recommended For You

About PGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PGEN--
Precigen, Inc.